Given the significant correlation between high expression of SP100 family members in PAAD and the occurrence, progression, and unfavorable prognosis of patients, it is plausible to propose that the association between TP53 mutation and the expression level of SP100 family members may underlie the role of SP100 family members in PAAD development. The gene discussed is TP53; the disease is pancreatic adenocarcinoma.